Peptide vaccines for hepatocellular carcinoma

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 1, 2013, Pages 210-212

  Nobuoka, Daisuke ^a,b   Yoshikawa, Toshiaki ^a   Sawada, Yu ^a   Fujiwara, Toshiyoshi ^b   Nakatsura, Tetsuya ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Clinical trial; Cytotoxic T lymphocyte; Glypican 3; Hepatocellular carcinoma; Peptide vaccine

Indexed keywords

CANCER VACCINE; GLYPICAN 3; PEPTIDE VACCINE;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG ANTIGENICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; LIVER CELL CARCINOMA; LIVER SURGERY; NONHUMAN; NOTE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; SURVIVAL TIME;

CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; GLYPICAN-3; HEPATOCELLULAR CARCINOMA; PEPTIDE VACCINE;

ANIMALS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE MODELS, ANIMAL; GLYPICANS; HUMANS; IMMUNOTHERAPY; MICE; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 84874735060     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22473     Document Type: Note

References (16)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108; PMID:15761078; http://dx.doi.org/10.3322/ canjclin.55.2.74.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90; PMID:18650514; http://dx.doi.org/10.1056/ NEJMoa0708857.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34; PMID:19095497; http://dx.doi.org/10.1016/S1470-2045(08)70285-7.
4. Greten TF, Forner A, Korangy F, N'Kontchou G, Barget N, Ayuso C, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010; 10:209; PMID:20478057; http://dx.doi.org/10.1186/1471-2407-10-209.
5. Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 2009; 27:130-9; PMID:19294626; http://dx.doi.org/10.1002/hon.886.
6. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012; 18:3686-96; PMID:22577059; http://dx.doi.org/10.1158/1078-0432.CCR-11-3044.
7. Filmus J. The contribution of in vivo manipulation of gene expression to the understanding of the function of glypicans. Glycoconj J 2002; 19:319-23; PMID:12975611; http://dx.doi.org/10.1023/A:1025312819804.
8. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306:16-25; PMID:12788060; http://dx.doi.org/10.1016/S0006-291X(03)00908-2.
9. Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Katagiri T, et al. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cellmediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 2004; 10:8630-40; PMID:15623647; http://dx.doi.org/10.1158/1078-0432.CCR- 04-1177.
10. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 2009; 34:649-56; PMID:19212669.
11. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009; 100:1403-7; PMID:19496787; http://dx.doi.org/10. 1111/j.1349-7006.2009.01206.x.
12. Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, et al. Identification of HLAA2-or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12:2689-97; PMID:16675560; http://dx.doi.org/10.1158/1078-0432.CCR-05- 2267.
13. Motomura Y, Ikuta Y, Kuronuma T, Komori H, Ito M, Tsuchihara M, et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int J Oncol 2008; 32:985-90; PMID:18425324.
14. Yoshikawa T, Nakatsugawa M, Suzuki S, Shirakawa H, Nobuoka D, Sakemura N, et al. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci 2011; 102:918-25; PMID:21281401; http://dx.doi.org/10. 1111/j.1349-7006.2011.01896.x.
15. Suzuki S, Yoshikawa T, Hirosawa T, Shibata K, Kikkawa F, Akatsuka Y, et al. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. Cancer Sci 2011; 102:1622-9; PMID:21668581; http://dx.doi.org/10.1111/j.1349-7006.2011.02003.x.
16. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21:233-40; PMID:19304471; http://dx.doi.org/10.1016/j. coi.2009.03.002.